샘플 요청 목록

 카트 문의
시장보고서
상품코드
1774810

세계의 뇌염 치료 시장

Encephalitis Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 478 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 뇌염 치료 시장은 2030년까지 275억 달러에 도달

2024년에 216억 달러로 추정되는 뇌염 치료 세계 시장은 2024-2030년의 분석 기간에 CAGR 4.1%로 성장하여 2030년에는 275억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 1차 뇌염은 CAGR 4.8%를 나타내고, 분석 기간 종료시에는 182억 달러에 이를 것으로 예측됩니다. 2차 뇌염 분야의 성장률은 분석 기간중 CAGR 2.7%로 추정됩니다.

미국 시장은 59억 달러로 추정, 중국은 CAGR 7.7%로 성장 예측

미국의 뇌염 치료 시장은 2024년에 59억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 57억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.7%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.6%와 3.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.4%로 성장할 전망입니다.

세계의 뇌염 치료 시장 - 주요 동향과 촉진요인 정리

뇌염이란 무엇이며, 왜 효과적인 치료가 중요한가?

뇌염은 뇌의 염증을 특징으로 하는 심각한 신경질환으로, 바이러스 감염, 자가면역질환 또는 세균성 병원체에 의해 발생하는 경우가 많습니다. 뇌염을 치료하지 않고 방치하면 장기적인 신경 합병증, 경련, 인지 기능 장애를 유발하고 심할 경우 사망에 이를 수도 있습니다. 일본뇌염, 웨스트 나일 바이러스, 지카 바이러스 등 모기 매개 뇌염 바이러스 증가로 인해 전 세계적으로 이 질환의 부담이 증가하고 있습니다. 또한, 단순 헤르페스 바이러스(HSV) 유발 뇌염과 자가면역성 뇌염의 유병률 증가로 인해 효과적인 항바이러스 및 면역 조절 요법에 대한 수요가 증가하고 있습니다.

중합효소연쇄반응(PCR) 검사, 뇌척수액 분석, MRI 영상진단 등 조기 진단법이 가능해짐에 따라 치료 성적이 향상되고 적시에 의료 개입이 가능해졌습니다. 병원과 연구기관들은 특히 아시아, 아프리카, 라틴아메리카의 고위험 지역에서 바이러스성 뇌염에 대항하기 위한 표적치료제와 백신 개발에 적극적으로 투자하고 있습니다. 또한, 모기 매개 뇌염 발생을 억제하기 위한 예방접종 프로그램 및 공중보건 노력에 대한 관심이 높아지고 있는 것도 시장 성장을 가속하고 있습니다.

뇌염 치료의 최신 동향은?

최근 뇌염 치료의 발전에는 새로운 항바이러스제, 단일클론항체, 면역조절요법 등이 있습니다. 바이러스성 뇌염의 경우, 단순 헤르페스 바이러스(HSV) 뇌염의 주요 치료제는 아시클로버이며, 새로운 광범위 항바이러스제가 신흥 바이러스 균주의 치료제로 검토되고 있습니다. 면역요법, 특히 면역글로불린 정맥주사(IVIG)와 부신피질 스테로이드는 자가면역성 뇌염 치료에 유망한 결과를 보이고 있습니다.

또한 연구자들은 뇌염을 유발하는 바이러스를 예방하기 위한 mRNA 기반 백신과 차세대 면역 전략을 개발하고 있으며, AI를 활용한 진단 플랫폼은 조기 발견과 치료 계획을 개선하고 합병증 위험을 줄이기 위해 AI를 활용하고 있습니다. 정밀의료 접근법의 통합에 대한 중요성이 강조되면서 뇌염 관리의 혁신을 촉진하고 생존율과 장기적인 회복 결과를 개선할 수 있을 것으로 기대됩니다.

뇌염 치료제 시장의 성장 원동력은?

뇌염 치료제 시장의 성장은 바이러스 발생 증가, 희귀 신경질환 연구에 대한 자금 지원 증가, 항바이러스 및 면역요법 치료의 발전으로 인한 것입니다. 특히 고위험 지역에서의 백신 프로그램 확대는 질병 예방에 대한 인식 제고와 헬스케어 투자로 이어지고 있습니다. 또한, 신경학 연구에서의 AI 활용 증가, 진단 능력의 향상, 제약회사와의 제휴를 통한 의약품 개발이 시장 개척을 촉진하고 있습니다.

정부의 공중 보건에 대한 노력, 전염병 대책 프로그램, 모기 퇴치 대책의 급증도 시장 확대에 기여하고 있습니다. 신경학적 합병증에 취약한 노인 인구 증가도 뇌염 치료에 대한 수요를 증가시키는 주요 요인입니다. 연구가 계속 발전함에 따라 유전자 치료, 생물학적 제제, 개인 맞춤형 의료 접근법의 획기적인 발전으로 뇌염 환자의 치료 옵션이 더욱 확대될 것으로 예측됩니다.

부문

질환 유형(원발성 뇌염, 이차성 뇌염);치료법(항바이러스제, 스테로이드 주사, 항생제, 면역글로불린 요법, 혈장 채집, 기타 치료법);투여 경로(경구, 비경구, 기타);최종사용자(병원, 전문 클리닉, 기타 최종사용자)

조사 대상 기업 예

  • Amgen, Inc.
  • Arialys Therapeutics
  • Basilea Pharmaceutica Ltd.
  • Bavarian Nordic A/S
  • Bayer AG
  • Bharat Biotech International Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi SA

AI 통합

당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.07.31

Global Encephalitis Treatment Market to Reach US$27.5 Billion by 2030

The global market for Encephalitis Treatment estimated at US$21.6 Billion in the year 2024, is expected to reach US$27.5 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Primary encephalitis, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$18.2 Billion by the end of the analysis period. Growth in the Secondary encephalitis segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.9 Billion While China is Forecast to Grow at 7.7% CAGR

The Encephalitis Treatment market in the U.S. is estimated at US$5.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.7 Billion by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Encephalitis Treatment Market - Key Trends & Drivers Summarized

What Is Encephalitis, and Why Is Effective Treatment Critical?

Encephalitis is a severe neurological condition characterized by inflammation of the brain, often caused by viral infections, autoimmune disorders, or bacterial pathogens. If left untreated, encephalitis can lead to long-term neurological complications, seizures, cognitive impairments, and, in severe cases, fatality. The growing incidence of mosquito-borne encephalitis viruses such as Japanese encephalitis, West Nile virus, and Zika virus has contributed to the increasing global burden of this disease. Additionally, the rising prevalence of herpes simplex virus (HSV)-induced encephalitis and autoimmune encephalitis has led to higher demand for effective antiviral and immunomodulatory therapies.

The availability of early diagnosis methods, such as polymerase chain reaction (PCR) testing, cerebrospinal fluid analysis, and MRI imaging, has improved treatment outcomes, enabling timely medical intervention. Hospitals and research institutions are actively investing in targeted therapies and vaccine development to combat viral-induced encephalitis, particularly in high-risk regions of Asia, Africa, and Latin America. The increasing focus on preventive vaccination programs and public health initiatives to curb mosquito-borne encephalitis outbreaks has also fueled market growth.

What Are the Latest Advancements in Encephalitis Treatment?

Recent advancements in encephalitis treatment include novel antiviral agents, monoclonal antibodies, and immune-modulating therapies. For viral encephalitis, acyclovir remains the primary treatment for herpes simplex virus (HSV) encephalitis, while newer broad-spectrum antiviral drugs are being explored for treating emerging viral strains. Immunotherapy, particularly intravenous immunoglobulin (IVIG) and corticosteroids, has shown promising results in managing autoimmune encephalitis cases.

Additionally, researchers are developing mRNA-based vaccines and next-generation immunization strategies to prevent encephalitis-causing viruses, particularly in endemic regions. AI-powered diagnostic platforms are also improving early detection and treatment planning, reducing the risk of complications. The growing emphasis on integrating precision medicine approaches is expected to drive innovation in encephalitis management, improving survival rates and long-term recovery outcomes.

What Is Driving the Growth of the Encephalitis Treatment Market?

The growth in the encephalitis treatment market is driven by rising viral outbreaks, increased funding for rare neurological disease research, and advancements in antiviral and immunotherapy treatments. The expansion of vaccine programs, particularly in high-risk regions, has led to greater disease prevention awareness and healthcare investments. Additionally, the increasing use of AI in neurology research, improved diagnostic capabilities, and pharmaceutical collaborations in drug development has propelled market expansion.

The surge in government public health initiatives, pandemic preparedness programs, and mosquito control measures has also contributed to market growth. The rising geriatric population, who are more susceptible to neurological complications, is another significant factor increasing demand for encephalitis treatments. As research continues to evolve, breakthroughs in gene therapy, biologics, and personalized medicine approaches are expected to further expand treatment options for encephalitis patients.

SCOPE OF STUDY:

The report analyzes the Encephalitis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Primary encephalitis, Secondary encephalitis); Treatment (Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis, Other treatments); Administration Route (Oral, Parenteral, Others); End-Use (Hospitals, Specialty clinics, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Amgen, Inc.
  • Arialys Therapeutics
  • Basilea Pharmaceutica Ltd.
  • Bavarian Nordic A/S
  • Bayer AG
  • Bharat Biotech International Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi SA

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Encephalitis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Viral Encephalitis Boosts Demand for Rapid Diagnostic and Treatment Solutions
    • Increased Vector-Borne Disease Transmission Drives Market for Antiviral and Anti-Inflammatory Therapies
    • Hospital ICU Expansion and Neurology Department Growth Strengthen Access to Encephalitis Management
    • Advancements in Imaging and Biomarkers Support Early Diagnosis and Targeted Drug Intervention
    • Immunocompromised Populations Spur Use of Prophylactic and Broad-Spectrum Encephalitis Treatments
    • Cross-Border Travel and Migration Patterns Raise Risk of Arboviral and Parainfectious Encephalitis
    • Neurocritical Care Protocol Development Enhances Standardization of Encephalitis Treatment Regimens
    • Development of Vaccine-Based Prophylaxis for Tick-Borne and Japanese Encephalitis Drives Prevention-Oriented Markets
    • Increased Awareness and Government Surveillance Initiatives Improve Early Case Detection and Access to Care
    • Rising Use of Immunoglobulin Therapy and Corticosteroids Supports Clinical Response in Autoimmune Cases
    • Biopharma R&D Pipelines Expand With Monoclonal Antibody-Based Treatments for Encephalitis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Encephalitis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Encephalitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Primary encephalitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Primary encephalitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Primary encephalitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Secondary encephalitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Secondary encephalitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Secondary encephalitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Antiviral agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Antiviral agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Antiviral agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Steroid injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Steroid injections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Steroid injections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Immunoglobulin therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Immunoglobulin therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Immunoglobulin therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Plasmapheresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Plasmapheresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Plasmapheresis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Other treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • JAPAN
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • CHINA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • EUROPE
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Encephalitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • FRANCE
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • GERMANY
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Spain 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Russia 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Europe 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Encephalitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Australia 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • INDIA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 221: India Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: India 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: South Korea 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Encephalitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Latin America 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Argentina 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Brazil 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Mexico 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Latin America 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Encephalitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Encephalitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Middle East 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Iran 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Israel 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Saudi Arabia 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: UAE 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Rest of Middle East 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030
  • AFRICA
    • Encephalitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Encephalitis Treatment by Disease Type - Primary encephalitis and Secondary encephalitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Encephalitis Treatment by Disease Type - Percentage Breakdown of Value Sales for Primary encephalitis and Secondary encephalitis for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Encephalitis Treatment by Administration Route - Parenteral, Others and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Encephalitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral, Others and Oral for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Encephalitis Treatment by End-Use - Hospitals, Specialty clinics and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Encephalitis Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty clinics and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Encephalitis Treatment by Treatment - Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Africa 15-Year Perspective for Encephalitis Treatment by Treatment - Percentage Breakdown of Value Sales for Antiviral agents, Steroid injections, Antibiotics, Immunoglobulin therapy, Plasmapheresis and Other treatments for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제